Download PDF
Der Nuklearmediziner 2013; 36(02): 107-112
DOI: 10.1055/s-0033-1345148
Lymphome: Diagnostik und Therapie
© Georg Thieme Verlag KG Stuttgart · New York

Radioimmuntherapie maligner Lymphome mit 90Yttrium-Ibritumomab-Tiuxetan: eine Bestands­aufnahme

Radioimmunotherapy of Malignant Lymphomas with 90Yttrium-Ibritumomab Tiuxetan: Overview of Current Use
A. Pezzutto
1   Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
,
C. W. Scholz
1   Medizinische Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin
› Author Affiliations
Further Information

Publication History

Publication Date:
24 June 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Radioimmuntherapie (RIT) mit 90Yttrium-­Ibritumomab-Tiuxetan wurde in der Europäischen Union im Jahre 2004 für die Behandlung des rezidivierten/refraktären follikulären Lymphoms zugelassen. Eine Erweiterung der Zulassung als Konsolidierungsmaßnahme nach Erstlinien-Chemoimmuntherapie wurde 2008 erteilt. Obwohl verschiedene Studien die hohe Wirksamkeit der RIT, gepaart mit ausgezeichneter Verträglichkeit, dokumentiert haben, bleibt diese therapeutische Option bei den meisten Lymphompatienten unbenutzt. In dieser Übersicht werden Daten zur Wirksamkeit der RIT beim follikulären Lymphom diskutiert, inklusive aktueller Daten, die eine hohe Wirksamkeit beim frühen Einsatz zeigen. Zusätzlich suggerieren vielversprechende Studienergebnisse eine mögliche Rolle der RIT im Rahmen einer (verkürzten) Chemoimmuntherapie bei hochmalignen Lymphomen oder als Teil einer Konditionierungstherapie vor autologer oder allogener Stammzelltransplantation.

Abstract

Radioimmunotherapy (RIT) with 90Yttrium-Ibritumomab Tiuxetan has been approved for treatment of relapsed follicular lymphoma in the European Union in 2004 and as consolidation therapy after first-line chemoimmunotherapy in order to improve the depth of remission in 2008. Although its effectivity paired with an excellent safety profile has been demonstrated in several clinical studies, this patient-friendly treatment remains largely underused in clinical practice. In this summary the high activity of RIT in indolent lymphoma including recent data supporting its use early in the course of the disease is reviewed, together with data indicating a possible role in aggressive lymphoma where RIT might have a role as consolidation after (shortened) chemoimmunotherapy or as part of the conditioning regimen prior to autologous or allogeneic transplantation.

Schlüsselwörter

90Y-Ibritumomab-Tiuxetan - Zevalin® - Radioimmuntherapie - Lymphom

Key words

90Y-Ibritumomab-Tiuxetan - Zevalin® - Radioimmunotherapy - Lymphoma
 

  • Literatur

  • 1 Bachy E, Brice P, Delarue R et al. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival – A study from the groupe d’etude des lymphomes de l’adulte. J Clin Oncol 2010; 28: 822-829
    CrossrefPubMedGoogle Scholar
  • 2 Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. J Clin Oncol 1997; 15: 1110-1117
    PubMedGoogle Scholar
  • 3 Czuczman MS, Emmanouilides C, Darif M et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 2007; 25: 4285-4292
    CrossrefPubMedGoogle Scholar
  • 4 DeNardo GL, DeNardo SJ, O’Grady LF et al. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 1990; 50: 1014s-1016s
    PubMedGoogle Scholar
  • 5 Hamlin PA, Rodriguez MA, Noy A et al. Final Results of a Phase II Study of Sequential R-CHOP and Yttrium-90 Ibritumomab Tiuxetan (RIT) for Elderly High Risk Patients with Untreated Diffuse Large B-Cell Lymphoma (DLBCL). ASH Annual Meeting Blood 2010; 116: 1793
    PubMedGoogle Scholar
  • 6 Kaminski MS, Fig LM, Zasadny KR et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992; 11: 1696-1711
    PubMedGoogle Scholar
  • 7 Kaminski MS, Zasadny KR, Francis IR et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-465
    CrossrefPubMedGoogle Scholar
  • 8 Kaminski MS, Armitage JO. Radioimmunotherapy in the treatment of non-Hodgkin’s lymphoma. J Natl Compr Canc Netw 2004; (Suppl. 03) 54-58
    PubMedGoogle Scholar
  • 9 Kaminski MS, Tuck M, Estes J et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441-449
    CrossrefPubMedGoogle Scholar
  • 10 Kaminski MS, Tuck M, Estes J et al. Tositumomab and Iodine I-131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma: Median 10 Year Follow-up Results. ASH Annual Meeting Abstracts. Blood 2012; 120: #3659
    PubMedGoogle Scholar
  • 11 Krishnan A, Nademanee A, Fung HC et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26: 90-95
    CrossrefPubMedGoogle Scholar
  • 12 Illidge TM, Pettengell R, Bayne M et al. Fractionated 90Y Ibritumomab-Tiuxetan (Zevalin®) Radioimmunotherapy as an Initial Therapy of Follicular Lymphoma – First Results From a Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. ASH Annual Meeting. Blood 2011; 118 # 102
    PubMedGoogle Scholar
  • 13 Lansigan F, Winer E, Metzler SR et al. Short Course of Bendamustine and Rituximab Followed by 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naïve Follicular Lymphoma: Early Results of “Fol-Brite” ASH Annual Meeting. Blood 2012; 120: #3657
    CrossrefPubMedGoogle Scholar
  • 14 Morschhauser F, Illidge T, Huglo D et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54-58
    CrossrefPubMedGoogle Scholar
  • 15 Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26: 5156-5164
    CrossrefPubMedGoogle Scholar
  • 16 Pica G, Nati S, Vitolo U et al. Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin’s Lymphoma (FL) Patients, An Italian Cooperative Study. ASH Annual Meeting Blood 2011; 118: #100
    PubMedGoogle Scholar
  • 17 Rose AC, Shenoy PJ, Garrett G et al. A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 2012; 12: 393-399
    CrossrefPubMedGoogle Scholar
  • 18 Salles G, Seymour JF, Offner F et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42-51
    CrossrefPubMedGoogle Scholar
  • 19 Scholz CW, Pinto A, Linkesch W et al. (90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial. J Clin Oncol 2013; 31: 308-313
    CrossrefPubMedGoogle Scholar
  • 20 Shimoni A, Avivi I, Rowe JM et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012; 118: 4706-4714
    CrossrefPubMedGoogle Scholar
  • 21 Smith MR, Li H, Gordon L et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 25: 3119-3126
    PubMedGoogle Scholar
  • 22 Vanazzi A, Grana Ch, Laszlo D et al. The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients. ASH Annual Meeting. Blood 2012; 120: #4876
    PubMedGoogle Scholar
  • 23 Van Oers MH, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006; 108: 3295-3301
    CrossrefPubMedGoogle Scholar
  • 24 Vose JM, Carter S, Burns LJ et al. Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial. J Clin Oncol 2013; [Epub ahead of print]
    PubMedGoogle Scholar
  • 25 Wilder RB, Jones D, Tucker SL et al. Long-term results with radiotherapy for Stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 2001; 51: 1219-1227
    CrossrefPubMedGoogle Scholar
  • 26 Winter JN, Inwards DJ, Spies S et al. Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin’s lymphoma. J Clin Oncol 2009; 27: 1653-1659
    CrossrefPubMedGoogle Scholar
  • 27 Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin’s lymphoma. Cancer Biother Radiopharm 2005; 2: 185-188
    PubMedGoogle Scholar
  • 28 Witzig TE, White CA, Wiseman GA et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol 1999; 12: 3793-3803
    PubMedGoogle Scholar
  • 29 Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol 2002; 20: 3262-3269
    CrossrefPubMedGoogle Scholar
  • 30 Zinzani PL, Rossi G, Franceschetti S et al. Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. Clin Cancer Res 2010; 15: 3998-4004
    PubMedGoogle Scholar